Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 16/20 | 0.55 |
| ▸ | TACR2 | P21452 | 14/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459898 | 0.99 | TACR2 (0.53) | TACR3TACR2KCNH2BCHEACHE | |
| SCHEMBL6851642 | 0.90 | TACR3 (0.54) | TACR3TACR2KCNH2OPRM1 | |
| SCHEMBL5461424 | 0.88 | TACR2 (0.53) | TACR3TACR2KCNH2OPRM1 | |
| SCHEMBL6853329 | 0.83 | TACR2 (0.57) | TACR3TACR2KCNH2OPRM1 | |
| SCHEMBL6853049 | 0.83 | TACR3 (0.58) | TACR3TACR2KCNH2OPRM1 | |
| SCHEMBL5455427 | 0.82 | TACR2 (0.53) | TACR3TACR2KCNH2OPRM1 | |
| SCHEMBL6853022 | 0.82 | TACR3 (0.51) | TACR3TACR2KCNH2OPRM1 | |
| SCHEMBL6266946 | 0.82 | TACR2 (0.59) | TACR3TACR2KCNH2OPRM1 | |
| SCHEMBL6851699 | 0.82 | TACR3 (0.67) | TACR3TACR2KCNH2OPRM1 | |
| SCHEMBL6853307 | 0.82 | TACR3 (0.54) | TACR3TACR2KCNH2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2007-01-18 | — | — | US | disclosed |
| US-20040082589-A1 | Quinoline derivatives as nk-3 and nk-2 antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2004-04-29 | — | — | US | disclosed |
| EP-1334089-A1 | QUINOLINE DERIVATIVES AS NK-3 AND NK-2 ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002038547-A1 | QUINOLINE DERIVATIVES AS NK-3 AND NK-2 ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082589-A1 | Quinoline derivatives as nk-3 and nk-2 antagonists | KCNH3, KCNH2, KCNK3 | TACR3 84/4885TACR2 24/4885KCNH2 2/4885 |
| US-20070015766-A1 | Quinoline Derivatives as NK-3 and NK-2 Antagonists | KCNK3, KCNQ3, ACKR3 | TACR3 41/4885TACR2 16/4885KCNH2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.